Author: Ken Dropiewski
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ANN ARBOR, Mich.–(BUSINESS WIRE)–Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients. In addition, the enhanced labels support the use of NEXLET
PrepMD and Magnifi Group Launch Annual EP Course for Fellows and Young Attendings
BRAINTREE, Mass., March 22, 2024 /PRNewswire/ — PrepMD, the leading provider of cardiac healthcare solutions, and Magnifi Group, Inc., renowned for its educational courses for Orthopedic Fellows, today announced partnership to create and manage an innovative annual Electrophysiology (EP)…
GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024
CHICAGO–(BUSINESS WIRE)–Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases and health conditions
US RADIOLOGY SPECIALISTS ANNOUNCES NEW CHIEF EXECUTIVE OFFICER & BOARD CHAIR
Veteran healthcare executive Lee Cooper will become CEO, and current US Radiology Board member Molly Joseph will become Board Chair. RALEIGH, N.C., March 21, 2024 /PRNewswire/ — US Radiology, one of the nation’s premier providers of diagnostic imaging services, announced that effective…
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
DENVER–(BUSINESS WIRE)–TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that the Company will present data from recent research findings at the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, to be held March 23-28, 2024, in Salt Lake City, Utah. TriSalus will share data on the technical feasibility and saf
Elixir Medical Receives FDA Breakthrough Device Designation for the DynamX BTK System for Use in the Treatment of Chronic Limb-Threatening Ischemia Resulting From Below-The-Knee Arterial Disease
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive technologies to treat cardiovascular and peripheral disease, today announced it has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its DynamX® BTK System, a novel, adaptive implant for use in the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients with chronic limb-threatening ischemia (CLTI). The DynamX Bioadaptor platform is a medical technology d
Stamford Health and Columbia University Irving Medical Center Deepen Relationship With Neurosciences Partnership
STAMFORD, Conn., March 21, 2024 /PRNewswire/ — Today, Stamford Health announced an expanded partnership with Columbia University Irving Medical Center (CUIMC) to increase its neurosurgical capabilities and expand its clinical team to treat a wider range of cerebrovascular conditions and…
Vista.ai Appoints MedTech Veteran Daniel Hawkins as Chief Executive Officer
PALO ALTO, Calif.–(BUSINESS WIRE)–VISTA.AI today announced the appointment of Daniel Hawkins as President and CEO. The company is pioneering AI-driven MRI image acquisition enabling any MRI technician to consistently produce high quality scans for complex indications quickly, efficiently and affordably. Daniel joins Vista.ai at a pivotal time following FDA clearance and confirmatory early commercialization of the company’s initial product focused on Cardiac MRI (CMR). Over time, the company p
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same day to
Recent
Solaris Endovascular Receives FDA Breakthrough Device Designation for Solaris DE™, a new Drug-Eluting Covered Stent
Embolization, Inc., Presents Novel Polymer-Based Coil at GEST, Booth No. 403
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
Popular
- No commented posts yet